Equinox Ophthalmic Closes Series C Financing
On August 5th, Stradling client Equinox Ophthalmic, Inc. consummated the initial closing of a $22 million Series C Preferred Stock financing. The initial closing of over $13 million included existing investors Visionary Venture Fund, Bluestem Ventures and Stradling client, Flying L Partners.
Equinox develops innovative solutions and treatments that promise better management for glaucoma patients through understanding, measuring, and controlling the balance of eye and brain pressures.